Table 1.
Clinical characteristics of patients included in the study.
| Cohort 1 (n = 312) | Cohort 2 (n = 15) | |||
|---|---|---|---|---|
| No. | % | No. | 15 | |
| Age at diagnosis | ||||
| < 50 yr | 197 | 63% | 6 | 40% |
| ≥ 50 yr | 115 | 37% | 9 | 60% |
| Treatment year | ||||
| Before 1997 | 125 | 40% | 0 | 0% |
| After 1997 | 187 | 60% | 15 | 100% |
| TNM Stage | ||||
| I | 67 | 21% | 2 | 13% |
| II | 139 | 45% | 8 | 53% |
| III | 98 | 31% | 5 | 33% |
| IV | 8 | 3% | 0 | 0% |
| Positive Lymph Nodes | ||||
| 0 | 132 | 42% | 5 | 33% |
| 1-3 | 83 | 27% | 5 | 33% |
| 4-9 | 58 | 19% | 3 | 20% |
| ≥ 10 | 35 | 11% | 2 | 13% |
| Unavailable | 4 | 1% | ||
| Nuclear Grade | ||||
| 1 | 25 | 8% | 8 | 53% |
| 2 | 83 | 27% | 7 | 47% |
| 3 | 202 | 65% | 0 | 0% |
| Unavailable | 2 | 1% | ||
| ER * | ||||
| ER+ | 190 | 61% | 14 | 93% |
| ER- | 122 | 39% | 1 | 7% |
| HER2* | ||||
| HER2+ | 74 | 24% | 1 | 7% |
| HER2- | 238 | 76% | 14 | 93% |
| PR* | ||||
| PR+ | 244 | 78% | 14 | 93% |
| PR- | 68 | 22% | 1 | 7% |
| Treatment | ||||
| Neoadjuvant Chemotherapy | 31 | 10% | 0 | 0% |
| Adjuvant Chemotherapy | 220 | 71% | 12 | 80% |
| Radiation Therapy | 133 | 43% | 8 | 53% |
| Hormonal Rx | 210 | 67% | 14 | 93% |
| No chemotherapy | 50 | 16% | 3 | 20% |
*: ER, HER2 and PR status were determined according to microarray data.